Russia Backs Second Drug In Development By Cleveland Biolabs
This article was originally published in PharmAsia News
Executive Summary
Russia's Ministry of Industry and Trade has signed a $4.6 million contract with Cleveland Biolabs to support its development of the cancer drug Mobilan, a nanoparticle adenovirus vaccine in pre-clinical testing by its Panacela Labs subsidiary.